E-LIB Suche - Ergebnisse für: Bruce Strober

1

Bimekizumab Safety and Tolerability in Moderate to Severe P..:

Gordon, Kenneth ; Thaçi, Diamant ; Gooderham, Melinda...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s404 , 2024

Link: https://doi.org/10.25251..

2

503 - Visualizing 3-year treatment outcome trajectories of ..:

Wang, Zhixiao ; Martins, Bruno ; Ardeleanu, Marius...
British Journal of Dermatology. 190 (2024) Supplement_2 - p. ii9-ii9 , 2024

Link: https://doi.org/10.1093/..

3

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Poo..:

Strober, Bruce ; Blauvelt, Andrew ; Warren, Richard B....
Journal of the European Academy of Dermatology and Venereology. 38 (2024) 8 - p. 1543-1554 , 2024

Link: https://doi.org/10.1111/..

4

P176 Ixekizumab significantly improves nail disease and adj..:

McGonagle, Dennis ; Kavanaugh, Arthur ; McInnes, Iain...
Rheumatology. 63 (2024) Supplement_1 - p. , 2024

Link: https://doi.org/10.1093/..

5

Bimekizumab Efficacy through Year 1 in Patients with Modera..:

Han, George ; Gottlieb, Alice ; Armstrong, April...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s369 , 2024

Link: https://doi.org/10.25251..

6

A randomized, double-blinded, phase 2 trial of EDP1815, an ..:

Ehst, Benjamin D. ; Strober, Bruce ; Blauvelt, Andrew...
Frontiers in Medicine. 11 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

7

Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Effi..:

Armstrong, April W. ; Lebwohl, Mark ; Warren, Richard B....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s406 , 2024

Link: https://doi.org/10.25251..

8

Effect of High-Dose Subcutaneous Spesolimab on Skin Manifes..:

Strober, Bruce ; Augustin, Matthias ; Tada, Yayoi...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 2 - p. s371 , 2024

Link: https://doi.org/10.25251..

9

Bimekizumab 3-year Safety and Tolerability in Moderate to S..:

Lebwohl, Mark ; Strober, Bruce ; Langley, Richard G....
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s305 , 2024

Link: https://doi.org/10.25251..

10

Real-world effectiveness of risankizumab in patients with m..:

Strober, Bruce ; Ferris, Laura ; Callis Duffin, Kristina...
Journal of the American Academy of Dermatology. 90 (2024) 1 - p. 82-90 , 2024

Link: https://doi.org/10.1016/..

11

Spesolimab Rapidly Improves Quality of Life in Patients wit..:

Gottlieb, Alice ; Strober, Bruce ; Kokolakis, Georgios...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 4 - p. s409 , 2024

Link: https://doi.org/10.25251..

12

Characterization of disease burden, treatment and comorbidi..:

Silverberg, Jonathan I. ; Cronin, Angel ; Jones, Eric A....
JAAD International. 15 (2024) - p. 127-130 , 2024

Link: https://doi.org/10.1016/..

13

Mental health outcomes in patients with moderate to severe ..:

Blauvelt, Andrew ; Armstrong, April ; Merola, Joseph F....
Journal of the American Academy of Dermatology. 91 (2024) 1 - p. 72-81 , 2024

Link: https://doi.org/10.1016/..

14

Efficacy of long‐term risankizumab treatment for moderate‐t..:

Strober, Bruce ; Bachelez, Hervé ; Crowley, Jeffrey...
Journal of the European Academy of Dermatology and Venereology. 38 (2024) 5 - p. 864-872 , 2024

Link: https://doi.org/10.1111/..

15

Association of the clinical components in the distal interp..:

McGonagle, Dennis ; Kavanaugh, Arthur ; McInnes, Iain B...
Rheumatology. , 2024

Link: https://doi.org/10.1093/..